The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]
Peter J. Goadsby, MD, PhD, DSc
Advertisement
Articles by Peter J. Goadsby, MD, PhD, DSc
How did erenumab's approval by the FDA change the landscape of migraine treatment?
Advertisement
Latest Updated Articles
Peter J. Goadsby, MD, PhD, DSc: Migraine Prevention Post-Approval of ErenumabPublished: August 26th 2018 | Updated:
Patient Selection of Novel Therapies for Migraine TreatmentPublished: October 28th 2020 | Updated:
Unmet Needs in the Management of MigrainePublished: October 28th 2020 | Updated:
Behavioral and Lifestyle Strategies for Migraine ManagementPublished: October 28th 2020 | Updated:
Acute Treatment of Migraine: Traditional TherapiesPublished: October 28th 2020 | Updated:
Role of Neuromodulation for Acute Treatment of MigrainePublished: October 28th 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
3
How Multiple Sclerosis Affects Men
4
Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds
5
